Detalhe da pesquisa
1.
Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.
Future Oncol
; 17(4): 403-409, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33028084
2.
Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.
Future Oncol
; 16(17): 1199-1210, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32363929
3.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 20(12): 1691-1701, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31669155
4.
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
N Engl J Med
; 375(23): 2246-2254, 2016 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27718781
5.
Real-world treatment patterns and outcomes of patients with stage IV squamous cell carcinoma of the head and neck.
Future Oncol
; 15(6): 611-623, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30426780
6.
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.
Future Oncol
; 15(17): 1997-2007, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31084373
7.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413378
8.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Lancet Oncol
; 18(12): 1590-1599, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074098
9.
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
BMC Cancer
; 16: 22, 2016 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26772734
10.
A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma.
Future Oncol
; 12(2): 175-82, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26674983
11.
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.
Lancet Oncol
; 16(6): 676-85, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25979595
12.
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Oncologist
; 20(3): 245-6, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25669662
13.
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
J Clin Oncol
; : JCO2400581, 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38819031
14.
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
J Thorac Oncol
; 18(11): 1581-1593, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37541389
15.
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
J Thorac Oncol
; 18(11): 1568-1580, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37295609
16.
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC.
JTO Clin Res Rep
; 4(5): 100499, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37223611
17.
Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests: A Blood Profiling Atlas in Cancer (BLOODPAC) Community Study.
J Mol Diagn
; 25(3): 143-155, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36828596
18.
Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
Bioorg Med Chem Lett
; 22(17): 5396-404, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22877636
19.
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Bioorg Med Chem Lett
; 22(24): 7653-8, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23127890
20.
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
J Clin Pharmacol
; 62(9): 1170-1176, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373356